Literature DB >> 3529677

[Clinical effectiveness of Spondyvit (vitamin E) in activated arthroses. A multicenter placebo-controlled double-blind study].

G Blankenhorn.   

Abstract

50 patients with osteoarthritis were randomly assigned to two groups and treated over a period of 6 weeks with vitamin E-capsules (daily dose 400 I.E. d-alpha-tocopherylacetate) or an identical placebo preparation. The results of this double-blind controlled clinical trial showed that vitamin E was superior to placebo with respect to the relief of pain (pain at rest, pain during movement, pressure-induced pain) and the necessity of additional analgetic treatment (p less than 0.05 to p less than 0.01). Improvement of mobility was better in the group treated with vitamin E. However, this result was not statistically significant. The profile and the intensity of adverse reactions in both the vitamin E and placebo group was practically identical. This clinical study shows antiphlogistic efficacy of vitamin E in patients with osteoarthritis. In view of the possibility to reduce standard antiphlogistic, analgetic therapy together with the very good tolerance this result may be very important for the treatment of chronic rheumatic inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3529677     DOI: 10.1055/s-2008-1044572

Source DB:  PubMed          Journal:  Z Orthop Ihre Grenzgeb        ISSN: 0044-3220


  12 in total

1.  Oxidative stress, vitamin e, and antioxidant capacity in knee osteoarthritis.

Authors:  Tanyawan Suantawee; Saran Tantavisut; Sirichai Adisakwattana; Aree Tanavalee; Pongsak Yuktanandana; Wilai Anomasiri; Benjamad Deepaisarnsakul; Sittisak Honsawek
Journal:  J Clin Diagn Res       Date:  2013-09-10

2.  Nutrition: risk factors for osteoarthritis.

Authors:  T McAlindon; D T Felson
Journal:  Ann Rheum Dis       Date:  1997-07       Impact factor: 19.103

3.  Putative analgesic activity of repeated oral doses of vitamin E in the treatment of rheumatoid arthritis. Results of a prospective placebo controlled double blind trial.

Authors:  S E Edmonds; P G Winyard; R Guo; B Kidd; P Merry; A Langrish-Smith; C Hansen; S Ramm; D R Blake
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

4.  Vitamin E is ineffective for symptomatic relief of knee osteoarthritis: a six month double blind, randomised, placebo controlled study.

Authors:  C Brand; J Snaddon; M Bailey; F Cicuttini
Journal:  Ann Rheum Dis       Date:  2001-10       Impact factor: 19.103

5.  Anti-inflammatory response of dietary vitamin E and its effects on pain and joint structures during early stages of surgically induced osteoarthritis in dogs.

Authors:  Mohamed Rhouma; Alexander de Oliveira El Warrak; Eric Troncy; Francis Beaudry; Younès Chorfi
Journal:  Can J Vet Res       Date:  2013-07       Impact factor: 1.310

6.  Does vitamin D affect femoral cartilage thickness? An ultrasonographic study.

Authors:  Fevziye Unsal Malas; Murat Kara; Lale Aktekin; Murat Ersöz; Levent Ozçakar
Journal:  Clin Rheumatol       Date:  2013-11-13       Impact factor: 2.980

Review 7.  The role of vitamin E in normal and damaged skin.

Authors:  F Nachbar; H C Korting
Journal:  J Mol Med (Berl)       Date:  1995-01       Impact factor: 4.599

Review 8.  Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence.

Authors:  Laurent G Ameye; Winnie S S Chee
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

9.  Can levels of antioxidants in synovial fluid predict the severity of primary knee osteoarthritis: a preliminary study.

Authors:  Chayanin Angthong; Noppawan Phumala Morales; Werasak Sutipornpalangkul; Anuwat Khadsongkram; Piya Pinsornsak; Boonchana Pongcharoen
Journal:  Springerplus       Date:  2013-12-05

Review 10.  Nutraceuticals: potential for chondroprotection and molecular targeting of osteoarthritis.

Authors:  Daniel J Leong; Marwa Choudhury; David M Hirsh; John A Hardin; Neil J Cobelli; Hui B Sun
Journal:  Int J Mol Sci       Date:  2013-11-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.